For the quarter ending 2025-09-30, OLMA had -$17,213K decrease in cash & cash equivalents over the period. -$34,527K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -42,217 | -74,173 |
| Depreciation and amortization expense | 43 | 260 |
| Non-cash lease expense | 300 | 575 |
| Non-cash interest income on marketable securities | 1,321 | 3,814 |
| Stock-based compensation expense, including employee stock purchase plan expense | 4,250 | 9,070 |
| Prepaid expenses and other current assets | -347 | 1,307 |
| Other assets and long-term deposits | 3,911 | 1,738 |
| Accounts payable | 2,391 | -3,566 |
| Other current liabilities | 5,902 | 1,451 |
| Operating lease liabilities | -311 | -620 |
| Net cash used in operating activities | -34,527 | -73,862 |
| Purchase of equipment | 0 | 0 |
| Maturities of marketable securities | 88,925 | 164,869 |
| Purchases of marketable securities | 71,652 | 175,718 |
| Net cash provided by investing activities | 17,273 | -10,849 |
| Issuance of shares under at-the-market offering, net of issuance costs of 166 | 0 | 0 |
| Issuance costs for shares issued under 2024 private placement | 6,514 | - |
| Proceeds from borrowings under credit facility (note 11) | 0 | 3,000 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 748 |
| Issuance costs for shares issued under 2024 equity private placement | - | 6,514 |
| Proceeds from exercise of stock options | 41 | 470 |
| Net cash (used in) provided by financing activities | 41 | -2,296 |
| Net decrease in cash and cash equivalents | -17,213 | -87,007 |
| Cash and cash equivalents at beginning of period | 139,480 | - |
| Cash and cash equivalents at end of period | 35,260 | - |
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)